Search clinical trials for: Actimyo°

Total 55 results

Laurent Servais
Centre Hospitalier Régional de la Citadelle; SYSNAV

Recruiting

Holter of Movement in Patients With Amyotrophic Lateral Sclerosis. (ActiALS)

Amyotrophic Lateral Sclerosis

Belgium
Laurent Servais
SYSNAV

Recruiting

Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study

Duchenne Muscular Dystrophy | Fascioscapulohumeral Muscular Dystrophy

Belgium
Centre Hospitalier Universitaire de Liege
Centre Hospitalier Régional de la Citadelle; SYSNAV

Recruiting

Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.

Amyotrophic Lateral Sclerosis

Belgium
Centre Hospitalier Universitaire de Liege
Centre Hospitalier Régional de la Citadelle; SYSNAV

Active, not recruiting

Holter of Movement in Patients With Multiple Sclerosis in Uncontrolled Environment.

Multiple Sclerosis

Belgium
Dr. Stéphanie Delstanche
SYSNAV; Centre Hospitalier Universitaire de Liege

Completed

Holter of Movement in Patients With Multiple Sclerosis in Controlled Environment.

Multiple Sclerosis

Belgium
Centre Hospitalier Universitaire de Liege
Centre Hospitalier Régional de la Citadelle; SYSNAV

Recruiting

Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility. (ActiCIDP)

Chronic Inflammatory Demyelinating Polyneuropathy

Belgium
Dr. Stéphanie Delstanche
Queen Fabiola Children's University Hospital; Erasme University Hospital; SYSNAV and other collaborators

Active, not recruiting

Holter of Movement in Patients With SMA Undergoing Treatment.

Spinal Muscular Atrophy

Belgium
Indiana University

Completed

Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis

Post-ERCP Acute Pancreatitis

United States
Northumbria Healthcare NHS Foundation Trust

Unknown

The Use of Compression Bandages in Total Knee Replacement Surgery

Osteoarthritis

United Kingdom
Assistance Publique Hopitaux De Marseille

Completed

Advantage of Detection of phIGFBP-1 to Reduce Hospitalization Time for Stable Patients With a Risk of Preterm Labour.

Patients With a Risk of Preterm Labour

France
Oxford University Clinical Research Unit, Vietnam
National Hospital for Tropical Diseases, Hanoi, Vietnam

Completed

Implementation of CRP Point of Care Testing in Primary Care to Improve Antibiotic Targeting in Respiratory Illness (ICAT) (ICAT)

Acute Respiratory Infection

Vietnam
Joseph Jurcic

Withdrawn

Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia
Danone Research

Completed

Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers

Respiratory Tract Infections | Pneumonia | Gastroenteritis | Sinusitis | Influenza | Healthy Subjects | Otitis | Infectious Diseases | Bronchitis | Sore Throat

Germany
Danone Research

Completed

Effect of the Consumption of a Fermented Milk on Common Infections in Children Aged 3-6 Years, Attending Day Care Centers

Common Infectious Diseases

Russian Federation
Fred Hutchinson Cancer Center
National Institute on Drug Abuse (NIDA)

Completed

mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation

Cigarette Smoking-Related Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom Macroglobulinemia

United States
Institut de Myologie, France

Completed

Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers (Pre-QuantiPark)

Parkinson Disease | Healthy Volunteers

France
Danone Research

Terminated

Effect of the Consumption of a Fermented Milk on Common Infections in Adults Submitted to Multi-stressor Situation

Gastroenteritis | Sinusitis | Otitis | Bronchitis | Upper Respiratory Tract Infections | Sore Throat | Flu | Lower Respiratory Tract Infections | Rhinopharyngitis | Pneumopathy | Flu-like Syndromes

France
National Cancer Institute (NCI)

Completed

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Neurofibromatosis Type 1 | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Visual Pathway Glioma

United States
Actinium Pharmaceuticals

Withdrawn

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML
University Hospital, Lille
Celgene Corporation

Completed

IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma (IFM2009-02)

Multiple Myeloma

France
Actinium Pharmaceuticals

Recruiting

Venetoclax and Lintuzumab-Ac225 in AML Patients

Acute Myeloid Leukemia | Relapsed Adult AML

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma

Recurrent Nervous System Lymphoma | Recurrent Primary Vitreoretinal DLBCL | Refractory Nervous System Lymphoma | Refractory Primary Vitreoretinal DLBCL

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of California, Los Angeles; Montefiore... and other collaborators

Active, not recruiting

Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection

Human Immunodeficiency Virus 1 Positive | Skin Kaposi Sarcoma

Uganda, Kenya, Malawi
OHSU Knight Cancer Institute
Sanofi; Oregon Health and Science University

Active, not recruiting

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

Cervical Intraepithelial Neoplasia Grade 2/3 | High Grade Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2

United States
Ashraf Badros
Merck Sharp & Dohme LLC

Terminated

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH); Amgen

Active, not recruiting

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma

United States
National Cancer Institute (NCI)

Completed

Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Actinium Pharmaceuticals

Completed

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

AML

United States, Puerto Rico
National Cancer Institute (NCI)

Completed

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy (S1115)

Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Pancreatic Acinar Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Pomalidomide Treatment in Patients With Kaposi Sarcoma

Skin Kaposi Sarcoma

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Multilineage Dysplasia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Oncotherapeutics
Celgene Corporation

Terminated

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Multiple Myeloma

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

Mucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Rectal Adenocarcinoma | Recurrent Rectal Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Emory University
National Cancer Institute (NCI); GlaxoSmithKline

Recruiting

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Plasma Cell Myeloma

United States
Medical College of Wisconsin

Active, not recruiting

Lintuzumab-Ac225 in Combination With Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Multiple Myeloma-Light Chain Only

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Intraocular Lymphoma | Central Nervous System Lymphoma | B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI); Janssen Scientific Affairs, LLC

Withdrawn

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Ohio State University Comprehensive Cancer Center
Celgene

Completed

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Recurrent Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Mayo Clinic

Active, not recruiting

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Plasma Cell Myeloma | Plasmacytoma | Plasma Cell Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
University of Washington
Genzyme, a Sanofi Company

Recruiting

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Epstein-Barr Virus Infection | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma | Stage II Nasopharyngeal Carcinoma

United States, Canada, Taiwan, Puerto Rico, Australia, Hong Kong, Singapore, China

Search clinical trials for: Actimyo°

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations